# US 2022/0031745 A1 · Antigen density sensing molecular circuits and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031745 A1
- Document ID: US20220031745A1
- Status: Published application
- Kind: A1
- Application number: 17/278,628
- Filed: 2019-09-26
- Published: 2022-02-03
- Earliest claimed: 2018-09-28
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Wendell A. Lim; Rogelio A. Hernandez-Lopez
- Web page: https://patentgrep.com/patent/US20220031745A1

## CPC

- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/50: containing protease site
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/715: containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/30: tumour cells
- C12N 2510/00: Genetically modified cells
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are antigen-density sensing molecular circuits and methods of using the same. Aspects of such circuits will generally include an antigen-triggered switch component and a therapeutic component specific for the same antigen as the antigen-triggered switch component. The circuits will generally be configured such that expression of the therapeutic component is induced by the antigen-triggered switch component when the switch is activated by binding the antigen. Nucleic acids, expression constructs, vectors and the like encoding such circuits, and cells genetically modified to include an antigen-density sensing molecular circuit are also provided. Also provided are methods of making antigen-density sensing molecular circuits, methods of inducing expression of high affinity therapeutics specific to an antigen expressed by a target cell, methods of activating an immune response to a target cell, methods of treating a subject for a cancer expressing an antigen, and the like, where such methods involve antigen-density sensing molecular circuits.

## Claims

### Claim 1

An antigen-density sensing molecular circuit comprising:
(a) a nucleic acid sequence encoding an antigen-triggered transcriptional switch that binds with low affinity to an antigen present on the surface of a target cell;
(b) a nucleic acid sequence encoding an antigen-specific therapeutic that binds with high affinity to the antigen; and
(c) a regulatory sequence operably linked to (b) that is activated by binding of the antigen-triggered transcriptional switch to the antigen to induce expression of the antigen-specific therapeutic.

### Claim 2 (depends on 1)

The molecular circuit according to claim 1, wherein the target cell is a cancer cell.

### Claim 3 (depends on 2)

The molecular circuit according to claim 2, wherein the antigen is selected from the group consisting of: Receptor tyrosine-protein kinase erbB-2 (HER2), CAMPATH-1 antigen (CD52), Programmed cell death 1 ligand 1 (PD-L1), Vascular endothelial growth factor (VEGF), B-lymphocyte antigen CD19 (CD19), Tumor necrosis factor receptor superfamily member 8 (CD30), Glutamate carboxypeptidase 2 (PSMA), Epidermal growth factor receptor (EGFR), disialoganglioside GD2 (GD2), SLAM family member 7 (SLAMF7), Myeloid cell surface antigen CD33 (CD33), B-lymphocyte antigen CD20 (CD20), B-cell receptor CD22 (CD22), Platelet-derived growth factor receptor alpha (PDGFRA), Vascular endothelial growth factor receptor 1 (VEGFR1), Vascular endothelial growth factor receptor 2 (VEGFR2), Mucin 1 (MCU1), Glutamate carboxypeptidase 2 (FOLH1), and Tyrosine-protein kinase receptor UFO (AXL).

### Claim 4

The molecular circuit according to any of the preceding claims, wherein the antigen-specific therapeutic comprises a single antigen-binding domain specific for the antigen.

### Claim 5 (depends on 1, 2, 3)

The molecular circuit according to any of claims 1 to 3, wherein the antigen-specific therapeutic comprises multiple antigen-binding domains specific for the antigen.

### Claim 6

The molecular circuit according to any of the preceding claims, wherein the antigen-triggered transcriptional switch comprises a single antigen-binding domain specific for the antigen.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The molecular circuit according to any of claims 1 to 5, wherein the antigen-triggered transcriptional switch comprises multiple antigen-binding domains specific for the antigen.

### Claim 8

The molecular circuit according to any of the preceding claims, wherein the antigen-specific therapeutic is a chimeric antigen receptor (CAR), a T cell receptor (TCR), or an antibody.

### Claim 9

The molecular circuit according to any of the preceding claims, wherein the antigen-triggered transcriptional switch comprises a Notch force sensor cleavage domain.

### Claim 10 (depends on 9)

The molecular circuit according to claim 9, wherein the antigen-triggered transcriptional switch is a synNotch polypeptide.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The molecular circuit according to any of claims 1 to 8, wherein the antigen-triggered transcriptional switch comprises a non-Notch force sensor cleavage domain.

### Claim 12 (depends on 11)

The molecular circuit according to claim 11, wherein the non-Notch force sensor cleavage domain comprises a von Willebrand Factor (vWF) cleavage domain.

### Claim 13

A cell genetically modified to comprise the molecular circuit of any of the preceding claims.

### Claim 14 (depends on 13)

The cell of claim 13, wherein the cell is an immune cell.

### Claim 15 (depends on 14)

The cell of claim 14, wherein the immune cell is a myeloid cell or a lymphoid cell.

### Claim 16 (depends on 15)

The cell of claim 15, wherein the immune cell is a lymphoid cell selected from the group consisting of: a T lymphocyte, a B lymphocyte and a Natural Killer cell.

### Claim 17 (depends on 13, 14, 15, 16)

The cell of any of claims 13 to 16, wherein the antigen-specific therapeutic is expressed on the surface of the cell.

### Claim 18 (depends on 13, 14, 15, 16)

The cell of any of claims 13 to 16, wherein the antigen-specific therapeutic is secreted by the cell.

### Claim 19

A method of making an antigen-density sensing molecular circuit, the method comprising:
obtaining a sequence encoding an antigen binding domain that binds to an antigen;
generating a modified antigen binding domain sequence encoding:
a high affinity modified antigen binding domain with increased affinity for the antigen as compared to the antigen binding domain; or
a low affinity modified antigen binding domain with decreased affinity for the antigen as compared to the antigen binding domain; and
generating a molecular circuit encoding an antigen-triggered transcriptional switch comprising the antigen binding domain that, when activated, induces expression of an antigen-specific therapeutic comprising the high affinity modified antigen binding domain; or
generating a molecular circuit encoding an antigen-triggered transcriptional switch comprising the low affinity modified antigen binding domain that, when activated, induces expression of an antigen-specific therapeutic comprising the antigen binding domain.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the antigen-specific therapeutic is a chimeric antigen receptor (CAR), a T cell receptor (TCR), or an antibody.

### Claim 21 (depends on 19, 20)

The method according to claims 19 or 20, wherein the antigen-triggered transcriptional switch comprises a Notch force sensor cleavage domain.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the antigen-triggered transcriptional switch is a synNotch polypeptide.

### Claim 23 (depends on 19, 20)

The method according to claims 19 or 20, wherein the antigen-triggered transcriptional switch comprises a non-Notch force sensor cleavage domain.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the non-Notch force sensor cleavage domain comprises a von Willebrand Factor (vWF) cleavage domain.

### Claim 25

A method of inducing expression of a high affinity therapeutic specific to an antigen expressed by a target cell in a subject in need thereof, the method comprising:
administering to the subject a cell genetically modified to comprise a molecular circuit comprising an antigen-triggered transcriptional switch that binds with low affinity to the antigen, wherein binding of the antigen-triggered transcriptional switch to the antigen induces expression of the high affinity therapeutic in the subject.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the antigen is a cancer antigen and the target cell is a cancer cell.

### Claim 27 (depends on 25, 26)

The method according to claims 25 or 26, wherein the high affinity therapeutic is a chimeric antigen receptor (CAR), a T cell receptor (TCR), or an antibody.

### Claim 28 (depends on 13, 14, 15, 16, 17, 18, 25, 26, 27)

The method according to any of claims 25-27, wherein the genetically modified cell is a cell according to any one of claims 13 to 18.

### Claim 29

A method of activating an immune response to a target cell expressing an antigen in a subject;
the method comprising:
administering to the subject an immune cell genetically modified to comprise a molecular circuit comprising an antigen-triggered transcriptional switch that binds with low affinity to the antigen to induce expression of an antigen-specific therapeutic that binds with high affinity to the antigen to activate the immune response in the subject.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 29)

The method according to claim 29, wherein the molecular circuit comprises an antigen-density sensing molecular circuit according to any one of claims 1 to 12.

### Claim 31

A method of treating a subject for a cancer expressing an antigen, the method comprising:
administering to the subject an effective amount of immune cells genetically modified to comprise a molecular circuit comprising an antigen-triggered transcriptional switch that binds with low affinity to the antigen to induce expression of an antigen-specific therapeutic that binds with high affinity to the antigen to activate an immune response in the subject, thereby treating the subject for the cancer.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the antigen is also expressed by non-cancer cells in the subject.

### Claim 33 (depends on 14, 15, 16, 31, 32)

The method according to claims 31 or 32, wherein the effective amount of immune cells comprises an immune cell according to any one of claims 14 to 16.
